November 6, 2003 - Norway Selects M Series Defibrillators for Major Installations

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832


Norway Selects ZOLL M Series Defibrillators for Major Installations

Corrected Version -  Thursday, November 06, 2003 – ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, today announced two agreements in Norway for ZOLL M Series defibrillators and accessories that have a market value in excess of $2 million. The first is with Helse Nord, the County Council of Northern Norway, for 168 units to be installed in all ambulances and most of the small medical clinics in this region. The second is with Norwegian Public Air Ambulance System for 19 units to be installed in more than half of their total fleet of helicopters countrywide, with an option to buy additional units. Training on the equipment delivered in September begins this month.

All of the ZOLL M Series defibrillators will transmit 12-lead electrocardiogram (ECG) data via land and mobile phone lines. In the Northern region where there are logistical challenges for emergency medicine, data transmission will be possible via satellite as well as GSM mobile coverage. ECG data will directly link to GE Medical Systems Information Technologies MUSE CV®. Two such systems will be installed as part of the Helse Nord agreement.

ZOLL and its exclusive Norway distributor, GE Medical Systems, were chosen after a thorough bidding process, which included six weeks of competitive equipment field testing. “The M Series’ proprietary technology, ease of use, low weight, and compact size were all factors in the decision of these customers to award their contracts to our team,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. Mr. Packer added that ZOLL accommodated a special request for a satellite communication method to address data transmission concerns of users in remote areas.

“As these deals confirm, data’s role has become increasingly important in the rescue process,” noted Mr. Packer. “The ability to instantly relay patient information from the field to the hospital can positively impact survival rates, which is why ZOLL has responded to customers’ needs with a total resuscitation package that includes both medical equipment and data management software solutions.”

ZOLL Medical Corporation (NASDAQ: ZOLL), with worldwide headquarters in Chelmsford, Massachusetts, designs, manufactures, and markets resuscitation solutions. Pacing and defibrillation devices, including LIFECOR, Inc.’s LifeVest™ Wearable Defibrillator and ZOLL’s M Series and AED Plus; and circulatory assist devices such as Advanced Circulatory Systems, Inc.’s ResQPOD™ Circulatory Enhancer and Revivant Corporation’s AutoPulse™; are used by health care professionals, emergency medical service providers, and first responders to diagnose and treat cardiac arrest wherever it may occur. ZOLL also designs and markets software that automates the collection and management of both clinical and non-clinical data. ZOLL has operations in the United States, Canada, the United Kingdom, Germany, France, the Netherlands, and Australia, and business partners in all of the world’s major markets. For more information about ZOLL, its products and partners, visit or call 978-421-9655.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, the intent, belief or current expectations of the Company, its directors or its officers, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2003.

# # #